A.G. Scientific, Inc. Mycophenolic Acid M-1036

Description
Immunosuppressive agent. Mycophenolic acid (MPA) has been tested extensively in renal transplant patients and has been shown to be effective in reducing the incidence of acute graft rejection. MPA is now being evaluated in combinations with tacrolimus (FK-506, Prod# F-1030) or sirolimus (Rapamycin, Prod# R-1018). It selectively inhibits lymphocyte proliferation by blocking the enzyme, inosine monophosphate dehydrogenase, part of in the guanosine monophosphate pathway. This enzyme is involved in the de novo synthesis of purine nucleotides1. * Inquire for bulk gram pricing**
Description
Immunosuppressive agent. Mycophenolic acid (MPA) has been tested extensively in renal transplant patients and has been shown to be effective in reducing the incidence of acute graft rejection. MPA is now being evaluated in combinations with tacrolimus (FK-506, Prod# F-1030) or sirolimus (Rapamycin, Prod# R-1018). It selectively inhibits lymphocyte proliferation by blocking the enzyme, inosine monophosphate dehydrogenase, part of in the guanosine monophosphate pathway. This enzyme is involved in the de novo synthesis of purine nucleotides1. * Inquire for bulk gram pricing**

Suppliers

Company
Product
Description
Supplier Links
San Diego, CA, USA
Mycophenolic Acid
M-1036
Mycophenolic Acid M-1036
Immunosuppressive agent. Mycophenolic acid (MPA) has been tested extensively in renal transplant patients and has been shown to be effective in reducing the incidence of acute graft rejection. MPA is now being evaluated in combinations with tacrolimus (FK-506, Prod# F-1030) or sirolimus (Rapamycin, Prod# R-1018). It selectively inhibits lymphocyte proliferation by blocking the enzyme, inosine monophosphate dehydrogenase, part of in the guanosine monophosphate pathway. This enzyme is involved in the de novo synthesis of purine nucleotides1. * Inquire for bulk gram pricing**

Immunosuppressive agent. Mycophenolic acid (MPA) has been tested extensively in renal transplant patients and has been shown to be effective in reducing the incidence of acute graft rejection. MPA is now being evaluated in combinations with tacrolimus (FK-506, Prod# F-1030) or sirolimus (Rapamycin, Prod# R-1018). It selectively inhibits lymphocyte proliferation by blocking the enzyme, inosine monophosphate dehydrogenase, part of in the guanosine monophosphate pathway. This enzyme is involved in the de novo synthesis of purine nucleotides1. * Inquire for bulk gram pricing**

Supplier's Site

Technical Specifications

  A.G. Scientific, Inc.
Product Category Organic Chemicals
Product Number M-1036
Product Name Mycophenolic Acid
Trigger Acid
Chemical Name 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Chemical Formula C17H20O6
Unlock Full Specs
to access all available technical data

Similar Products

DMI 1,3 Dimethyl-2-Imidazolidinone -  - Mitsui Chemicals America, Inc.
Mitsui Chemicals America, Inc.
Specs
Trigger Solvent
Chemical Name DMI 1,3 Dimethyl-2-Imidazolidinone
State of Matter Liquid / Solution
View Details
AMOLEA™ HCFO Solvents -  - AGC Chemicals Americas, Inc.
AGC Chemicals Americas, Inc.
Specs
Trigger Solvent
Chemical Family All Alkenes
Chemical Name Hydrochlorofluoroolefin
View Details
Wintersun Chemical
Specs
Chemical Name 4-Hexyl Resorcinol
Chemical Formula C12H18O2
CAS Number 136-77-6
View Details